[{"AccountsPayableCurrent_0_Q1_USD":5173000.0,"FairValueLiabilitiesLevel1ToLevel2TransfersAmount_0_Q1_USD":0.0,"FairValueAssetsLevel2ToLevel1TransfersAmount_0_Q1_USD":0.0,"FairValueAssetsLevel1ToLevel2TransfersAmount_0_Q1_USD":0.0,"DebtSecuritiesAvailableForSaleRealizedGainLoss_1_Q1_USD":0.0,"ContractWithCustomerLiabilityNoncurrent_0_Q1_USD":3124000.0,"ContractWithCustomerLiabilityCurrent_0_Q1_USD":2923000.0,"ContractWithCustomerAssetNetNoncurrent_0_Q1_USD":1170000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1_Q1_USD":-1448000.0,"FairValueLiabilitiesLevel2ToLevel1TransfersAmount_0_Q1_USD":0.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q1_USD":98593000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q1_USD":6913000.0,"AccretionAmortizationOfDiscountsAndPremiumsInvestments_1_Q1_USD":-271000.0,"LongTermInvestments_0_Q1_USD":16139000.0,"AllocatedShareBasedCompensationExpense_1_Q1_USD":6913000.0,"IncreaseDecreaseInContractWithCustomerLiability_1_Q1_USD":-515000.0,"ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1_Q1_USD":-33400000.0,"AccruedSalariesCurrent_0_Q1_USD":3059000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q1_USD":120000.0,"CapitalizedContractCostAmortization_1_Q1_USD":168000.0,"ProceedsFromStockOptionsExercised_1_Q1_USD":1011000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q1_USD":195681000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0_Q1_USD":12988000.0,"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1_Q1_USD":47808000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q1_USD":2515000.0,"RestrictedCashNoncurrent_0_Q1_USD":15227000.0,"RestrictedCashAndCashEquivalentsNoncurrent_0_Q1_USD":15227000.0,"ProceedsFromSaleMaturityAndCollectionsOfInvestments_1_Q1_USD":24844000.0,"OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_1_Q1_USD":0.0,"OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld_0_Q1_USD":0.0,"OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1_Q1_USD":120000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0_Q1_USD":13378000.0,"OperatingLeaseWeightedAverageDiscountRatePercent_0_Q1_pure":0.084,"OperatingLeaseLiabilityNoncurrent_0_Q1_USD":73834000.0,"OperatingLeaseLiabilityCurrent_0_Q1_USD":1898000.0,"OperatingLeaseLiability_0_Q1_USD":75732000.0,"LettersOfCreditOutstandingAmount_0_Q1_USD":15200000.0,"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0_Q1_USD":90678000.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q1_USD":2938000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q1_USD":9541000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q1_USD":12610000.0,"OperatingLeaseRightOfUseAsset_0_Q1_USD":69200000.0,"InvestmentIncomeInterest_1_Q1_USD":972000.0,"DepreciationDepletionAndAmortization_1_Q1_USD":705000.0,"OperatingLeaseExpense_1_Q1_USD":3500000.0,"NetIncomeLoss_1_Q1_USD":-33520000.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-26673000.0,"NetCashProvidedByUsedInInvestingActivities_1_Q1_USD":23774000.0,"NetCashProvidedByUsedInFinancingActivities_1_Q1_USD":1451000.0,"LiabilitiesCurrent_0_Q1_USD":24924000.0,"LiabilitiesAndStockholdersEquity_0_Q1_USD":321890000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1_Q1_USD":-636000.0,"GeneralAndAdministrativeExpense_1_Q1_USD":7729000.0,"PaymentsToAcquirePropertyPlantAndEquipment_1_Q1_USD":1070000.0,"EarningsPerShareBasicAndDiluted_1_Q1_USD":-0.44,"CommonStockSharesOutstanding_0_Q1_shares":75996075.0,"CommonStockSharesIssued_0_Q1_shares":75996075.0,"CashAndCashEquivalentsAtCarryingValue_0_Q1_USD":83366000.0,"AssetsCurrent_0_Q1_USD":208249000.0,"Assets_0_Q1_USD":321890000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q1_shares":25900000.0,"AdditionalPaidInCapital_0_Q1_USD":636062000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q1_USD":142000.0,"CommonStockValue_0_Q1_USD":76000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q1_USD":4965000.0,"ProfitLoss_1_Q1_USD":-33520000.0,"PropertyPlantAndEquipmentNet_0_Q1_USD":11896000.0,"OtherAccruedLiabilitiesCurrent_0_Q1_USD":3238000.0,"OtherAssetsNoncurrent_0_Q1_USD":9000.0,"CapitalExpendituresIncurredButNotYetPaid_1_Q1_USD":343000.0,"OtherNonoperatingIncomeExpense_1_Q1_USD":972000.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1_Q1_USD":-3316000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q1_USD":949000.0,"ResearchAndDevelopmentExpense_1_Q1_USD":29278000.0,"PreferredStockValue_0_Q1_USD":3000.0,"PreferredStockSharesAuthorized_0_Q1_shares":5000000.0,"PreferredStockParOrStatedValuePerShare_0_Q1_USD":0.001,"OperatingIncomeLoss_1_Q1_USD":-34492000.0,"OperatingExpenses_1_Q1_USD":37007000.0,"CommonStockSharesAuthorized_0_Q1_shares":150000000.0,"CommonStockParOrStatedValuePerShare_0_Q1_USD":0.001,"CommitmentsAndContingencies_0_Q1_USD":null,"AccruedLiabilitiesCurrent_0_Q1_USD":11770000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q1_shares":75886964.0,"StockholdersEquity_0_Q1_USD":219218000.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":-417065000.0,"ShortTermLeaseCost_1_Q1_USD":600000.0,"VariableLeaseCost_1_Q1_USD":600000.0,"Ticker":"FATE","CIK":"1434316","name":"FATE THERAPEUTICS INC","OfficialName":"Fate Therapeutics Inc. Common Stock","form":"10-Q","period":"20200331","fy":"2020.0","fp":"Q1","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"3545646272.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20200511"}]